Who are Ketamine , Lidocaine , Dexmedetomidine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ketamine-lidocaine-dexmedetomidine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Ketamine , Lidocaine , Dexmedetomidine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ketamine , Lidocaine , Dexmedetomidine (Ketamine , Lidocaine , Dexmedetomidine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anesthetic combination / Sedative-analgesic combination. Area: Anesthesiology / Pain Management.

phase 3 Anesthetic combination / Sedative-analgesic combination NMDA receptor (ketamine), voltage-gated sodium channels (lidocaine), alpha-2 adrenergic receptors (dexmedetomidine) Anesthesiology / Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Ketamine , Lidocaine , Dexmedetomidine (Ketamine , Lidocaine , Dexmedetomidine) — University of Saskatchewan. This is a fixed-dose combination of three agents that work synergistically: ketamine blocks NMDA receptors for anesthesia/analgesia, lidocaine blocks sodium channels for local anesthesia, and dexmedetomidine activates alpha-2 adrenergic receptors for sedation and analgesia.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ketamine , Lidocaine , Dexmedetomidine TARGET	Ketamine , Lidocaine , Dexmedetomidine	University of Saskatchewan	phase 3	Anesthetic combination / Sedative-analgesic combination	NMDA receptor (ketamine), voltage-gated sodium channels (lidocaine), alpha-2 adrenergic receptors (dexmedetomidine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anesthetic combination / Sedative-analgesic combination class)

University of Saskatchewan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ketamine , Lidocaine , Dexmedetomidine — Competitive Intelligence Brief. https://druglandscape.com/ci/ketamine-lidocaine-dexmedetomidine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab